Myeloma generally refers to multiple myeloma. When multiple myeloma patients fail to obtain very good partial remission after induction therapy, they can also benefit from autologous hematopoietic stem cell transplantation, therefore, when the patients are eligible for transplantation, they should actively undergo autologous transplantation. Multiple myeloma is most common in elderly patients. In recent years, proteasome inhibitors, immunomodulators, monoclonal antibodies and other treatments have been emerging, and their survival rates have been significantly improved, including bortezomib, lenalidomide, daltuzumab, etc. However, for patients younger than 65 years of age, who have not received a good partial remission after induction therapy, they can benefit from autologous HSCT. However, autologous hematopoietic stem cell transplantation is still recommended for patients younger than 65 years of age who have a chance of transplantation, and can allow patients to achieve deep remission of the disease by aggressively pursuing autologous hematopoietic stem cell transplantation after four standard chemotherapy treatments. At which period of time multiple myeloma patients need to undergo transplantation, it is necessary for doctors to determine the final treatment plan according to the patient’s specific situation, and the prognosis is also related to the patient’s tumor stage, type, treatment plan, etc. Specific treatment and medication should be carried out under the guidance of physicians.